Dexcom (DXCM): Sen. John Boozman disclosed a purchase $1K–$15K
Sen. John Boozman disclosed a purchase of Dexcom in the $1K–$15K range.
- $1,001–$15,000
- Reported range · official band, not an exact amount
- 20 days
- Disclosure lag
- Traded
- Jan 26, 2026
- Disclosed
- Feb 15, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Dec 17, 2025FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System
- Dec 19, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously reported on the Current Report on Form 8-K filed on July 30, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jacob S. Leach, President and Chief Operating Officer, as the President and Chief Executive Officer and as a director of the Company, effective January 1, 2026, following Kevin R. Sayer’s resignation, effective as of such date.”
- Jan 7, 2026Company filing · Form 8-K · ResultsReported its results
- Jan 26, 2026 · this disclosureCongressDisclosed purchase of DXCM — reported range $1,001 - $15,000
What came next
- Feb 3, 2026FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System; Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System
- Feb 12, 2026Company filing · Form 8-K · ResultsReported its results
- Feb 12, 2026InsiderDirector sold ~$69K of DXCM shares in the open market
- Feb 26, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On February 26, 2026, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to twelve directors and appointed Albert F. (“Rick”) Osterloh, IV as a director effective immediately.”
- Feb 27, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously reported on the Current Report on Form 8-K filed on July 30, 2025, Kevin R. Sayer notified the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) of his intent to retire from his role as Chief Executive Officer effective January 1, 2026.”
- Mar 16, 2026InsiderOfficer sold ~$110K of DXCM shares in the open market
- Mar 26, 20265% stakeThe Vanguard Group reported a passive stake (13G)
- Apr 14, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM watchOS App Model/Catalog Number: SW13355 Software Version: Versions 2.9…
- Apr 14, 2026FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM iOS App Model/Catalog Number: SW12300 Software Version: Versions 2.9.0 t…
- Apr 14, 2026FDARecall: Brand Name: Dexcom ONE+ Continuous Glucose Monitoring System Product Name: Dexcom ONE+ iOS CGM App Model/Catalog Number: SW14244 Software Version: versions 1.5…
- Apr 15, 2026InsiderOfficer sold ~$107K of DXCM shares in the open market
- Apr 29, 20265% stakeVanguard Portfolio Management reported a passive stake (13G) of 5.0%
- Apr 29, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
- Apr 29, 2026CongressDisclosed partial sale of DXCM — reported range $100,001 - $250,000
- Apr 30, 2026Company filing · Form 8-K · ResultsReported its results
- May 7, 2026CongressDisclosed sale of DXCM — reported range $100,001 - $250,000
- May 12, 2026InsiderDirector sold ~$61K of DXCM shares in the open market
- May 15, 2026InsiderOfficer sold ~$102K of DXCM shares in the open market
- May 21, 2026FDAFDA device clearance: Stelo Glucose Biosensor System
- May 21, 2026InsiderChair sold ~$1.93M of DXCM shares in the open market
How to read Senate eFD periodic transaction report
The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.
Full guide: What is the STOCK Act?
What else is on file for Dexcom
For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.
Other recent filings by Sen. John Boozman
- Senate eFD periodic transaction report at Cisco (CSCO)Oct 21, 2026
- Senate eFD periodic transaction report at Realty Income (O)Oct 21, 2026
- Senate eFD periodic transaction report at Aptiv (APTV)Oct 21, 2026
- Senate eFD periodic transaction report at Micron (MU)Oct 21, 2026
- Senate eFD periodic transaction report at Micron (MU)Oct 21, 2026
The full history of Sen. John Boozman is on the profile page.
How this filing works
Explore the data
Common questions
Which member of Congress traded Dexcom (DXCM) stock, and how much?
Sen. John Boozman disclosed a purchase of Dexcom in the $1K–$15K range. Reported range, not an exact amount, Joint account.
When did it happen, and when was it made public?
Traded: Jan 26, 2026. Disclosed: Feb 15, 2026. That is 20 days between the two dates.
Why is the amount a range and not an exact figure?
Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.
Where does this information come from?
From the Senate eFD periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Dexcom recently?
For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the DXCM page.
Does this mean DXCM stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Dexcom
- SEC Form 4Nov 18, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 144Nov 16, 2026
- SEC Form 4Oct 28, 2026
- SEC Form 144Oct 27, 2026
- SEC Form 4Oct 19, 2026
Everything OQRO holds on this company is on its DXCM page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
